Market

This penny stock $OBSV could skyrocket 100% in 2021 for NASDAQ:OBSV by AlenCiken

The company’s lead drug candidate, linzagolix (branded as Yselty), is an orally administered GnRH receptor antagonist that has completed two Phase 3 studies, PRIMROSE 1 in the US and PRIMROSE 2 in both the US and Europe. The clinical trials enrolled 574 and 535 patients, respectively, and used doses of 100mg or 200mg to treat heavy menstrual bleeding associated with uterine fibroids. The results from both studies were positive, supporting Linzagolix’s favorable safety and efficacy profile.

In an update announced last month, ObsEva reported that, pursuant to Phase 3 results, the European Medicines Agency ( EMA ) had validated for review the company’s Marketing Authorization Application ( MAA ) for Yselty (100mg and 200mg). Potential MAA approval is anticipated in Q4:21. The drug is also slated to be the subject of a New Drug Application ( NDA ) that is due to be submitted to the FDA in Q2.

Wedbush analyst Liana Moussatos said that Linzagolix has the potential to achieve best-in class oral GnRH receptor antagonist status based on a flexible dosing regimen either with or without the add-back hormone therapy ( ABT )—a key differentiator from other GnRH receptor antagonists… Based on the positive PRIMROSE 1 and PRIMROSE 2 primary endpoint results for YSELTY®/UF and additional follow-up data, we project annual sales of more than $750 million in 2027 for Linzagolix/UF,” Moussatos opined.

To this end, Moussatos rates OBSV a Buy along with a $28 price target.

https://finance.yahoo.com/news/2-strong-…

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button